Kim A. Connelly

FRACP, PhD, MBBS

Scientist

Biography

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. His work has been recognized evident by winning the “Young Investigator of the Year Award” by the Canadian Cardiovascular Society, an Early Researcher Award in 2014, and a CIHR New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He developed the first hemodynamically validated model of diabetes induced HFpEF. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses regenerative cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He has research support from the HSF of Canada, CIHR and CFI along with significant research support from the pharmaceutical industry. His work has been published in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes.

His H index is 45, and I index of 140.

Dr Connelly is immediate past president of the Canadian Society of Cardiac Magnetic resonance imaging. He runs a translational imaging laboratory and uses hyperpolarized C13 metabolic imaging to understand metabolism in the human heart in real time, as well as CMR to understand the impact of exercise upon cardiac remodeling. He was senior author of the EMPA HEART study along with Dr Verma and Zinman to assess the mechanism by which the SGLT2i empagliflozin provided cardiac protection in patients with type 2 DM. Finally, he was past section lead of 2018 macrovascular complications section for the Diabetes Canada Clinical practice updates and is current chair of the Canadian Cardiovascular Society guidelines.

Recent Publications

  1. Hibino, M, Dhingra, NK, Verma, S, Chan, V, Quan, A, Gregory, AJ et al.. Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trial. J Thorac Cardiovasc Surg. 2021; :. doi: 10.1016/j.jtcvs.2021.08.081. PubMed PMID:34702564 .
  2. Tan, NS, Deva, DP, Connelly, KA, Angaran, P, Mangat, I, Jimenez-Juan, L et al.. Myocardial strain assessment using cardiovascular magnetic resonance imaging in recipients of implantable cardioverter defibrillators. J Cardiovasc Magn Reson. 2021;23 (1):115. doi: 10.1186/s12968-021-00806-4. PubMed PMID:34670574 PubMed Central PMC8529844.
  3. Grimmer, B, Krauszman, A, Hu, X, Kabir, G, Connelly, KA, Li, M et al.. Pannexin 1-a novel regulator of acute hypoxic pulmonary vasoconstriction. Cardiovasc Res. 2021; :. doi: 10.1093/cvr/cvab326. PubMed PMID:34668529 .
  4. Sarak, B, Verma, S, David Mazer, C, Teoh, H, Quan, A, Gilbert, RE et al.. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovasc Diabetol. 2021;20 (1):200. doi: 10.1186/s12933-021-01390-8. PubMed PMID:34607574 PubMed Central PMC8491405.
  5. Glibbery, M, Banks, L, Altaha, MA, Bentley, RF, Konieczny, K, Yan, AT et al.. Atrial structure and function in middle-aged, physically-active males and females: A cardiac magnetic resonance study. Clin Cardiol. 2021;44 (10):1467-1474. doi: 10.1002/clc.23707. PubMed PMID:34469002 PubMed Central PMC8495091.
  6. Jimenez-Juan, L, Ben-Dov, N, Goncalves Frazao, CV, Tan, NS, Singh, SM, Dorian, P et al.. Right Ventricular Function at Cardiac MRI Predicts Cardiovascular Events in Patients with an Implantable Cardioverter-Defibrillator. Radiology. 2021;301 (2):322-329. doi: 10.1148/radiol.2021210246. PubMed PMID:34402663 .
  7. Hare, GMT, Zhang, Y, Chin, K, Thai, K, Jacobs, E, Cazorla-Bak, MP et al.. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. Physiol Rep. 2021;9 (12):e14890. doi: 10.14814/phy2.14890. PubMed PMID:34184431 PubMed Central PMC8239445.
  8. Sharma, A, Aziz, H, Verma, S, Abramson, BL, Choi, R, Chua, GL et al.. Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. Curr Opin Cardiol. 2021;36 (5):672-681. doi: 10.1097/HCO.0000000000000892. PubMed PMID:34173772 .
  9. Meagher, P, Civitarese, R, Lee, X, Gordon, M, Bugyei-Twum, A, Desjardins, JF et al.. The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function. PLoS One. 2021;16 (6):e0252711. doi: 10.1371/journal.pone.0252711. PubMed PMID:34166385 PubMed Central PMC8224913.
  10. Primary Panel, Ian Paterson, D, White, JA, Butler, CR, Connelly, KA, Guerra, PG et al.. 2021 Update on Safety of Magnetic Resonance Imaging: Joint Statement From Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society. Can J Cardiol. 2021;37 (6):835-847. doi: 10.1016/j.cjca.2021.02.012. PubMed PMID:34154798 .
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre
X